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Strengths and limitations of this study
 ► Large cohort and nested case–control studies based 
on whole population routinely collected health data 
from primary and secondary care.
 ► We are unable to quantify how many people are 
suffering from hypermobile Ehlers- Danlos syndrome 
(hEDS) or hypermobility spectrum disorder but re-
main undiagnosed, nor can we make any statement 
on the reliability of the diagnoses.
 ► Although we only compared codes at Read chap-
ter level, all diagnoses and prescriptions can be 
matched to conditions found in the EDS/joint hyper-
mobility syndrome literature.
AbStrACt
Objectives To describe the epidemiology of diagnosed 
hypermobility spectrum disorder (HSD) and Ehlers- Danlos 
syndromes (EDS) using linked electronic medical records. 
To examine whether these conditions remain rare and 
primarily affect the musculoskeletal system.
Design Nationwide linked electronic cohort and nested 
case–control study.
Setting Routinely collected data from primary care and 
hospital admissions in Wales, UK.
Participants People within the primary care or hospital 
data systems with a coded diagnosis of EDS or joint 
hypermobility syndrome (JHS) between 1 July 1990 and 
30 June 2017.
Main outcome measures Combined prevalence of JHS 
and EDS in Wales. Additional diagnosis and prescription 
data in those diagnosed with EDS or JHS compared with 
matched controls.
results We found 6021 individuals (men: 30%, women: 
70%) with a diagnostic code of either EDS or JHS. This 
gives a diagnosed point prevalence of 194.2 per 100 000 
in 2016/2017 or roughly 10 cases in a practice of 5000 
patients. There was a pronounced gender difference of 8.5 
years (95% CI: 7.70 to 9.22) in the mean age at diagnosis. 
EDS or JHS was not only associated with high odds for 
other musculoskeletal diagnoses and drug prescriptions 
but also with significantly higher odds of a diagnosis 
in other disease categories (eg, mental health, nervous 
and digestive systems) and higher odds of a prescription 
in most disease categories (eg, gastrointestinal and 
cardiovascular drugs) within the 12 months before and 
after the first recorded diagnosis.
Conclusions EDS and JHS (since March 2017 classified 
as EDS or HSD) have historically been considered rare 
diseases only affecting the musculoskeletal system and 
soft tissues. These data demonstrate that both these 
assertions should be reconsidered.
IntrODuCtIOn
The Ehlers- Danlos syndromes (EDS) are a 
group of hereditary connective tissue disor-
ders which mainly affect collagen. The nomen-
clature of these conditions has undergone a 
number of iterations which makes discussion 
of their prevalence complicated (box 1).
For many decades, studies have quoted a 
prevalence rate of 1 in 5000 for EDS, although 
the origin of this figure is unclear, seeming 
to appear first in a medical textbook1 2 as an 
unreferenced ‘reasonable estimate’. Thus, 
these syndromes have long been categorised 
as rare diseases, defined in the European 
Union as those affecting fewer than 50 in 
100 000 people.3 Kulas Søborg et al4 recently 
reported a prevalence of 20 per 100 000 for 
EDS in a nationwide Danish cohort based 
on secondary healthcare data up to 2012, 
but importantly, this data did not include 
patients who had received the considerably 
more common joint hypermobility syndrome 
(JHS) diagnosis, now included in the latest 
revised classification. It is possible to extrapo-
late a combined population prevalence figure 
for JHS and EDS for Sweden5 of around 
120 per 100 000 from a study focusing on 
comorbid mental health issues, but no inves-
tigators have thus far set out to investigate the 
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box 1 An overview of the Ehlers- Danlos nomenclature
 ► Joint hypermobility per se is reasonably common and thought to be 
present in around 10% of the general UK population.40
 ► The Brighton criteria were used to diagnose joint hypermobility syn-
drome (JHS) from 1998.41
 ► The Villefranche criteria were applied to confirm EDS- hypermobility 
type (EDS- HT) from 1997.42
 ► Prior to the Villefranche criteria, the diagnosis EDS III was used to 
denote the hypermobile subtype of EDS.
 ► It was recognised over a number of years that JHS and EDS- HT were 
not distinct from one another.43
 ► In March 2017, the International Consortium on the Ehlers- Danlos 
syndromes published a revised classification44 naming two 
syndromes:
Hypermobile EDS (hEDS) which has narrowly defined criteria.
Hypermobility spectrum disorder (HSD) for those with some but not 
all the features of hEDS.
 ► Patients who have a diagnosis of EDS- HT or JHS will fall into one of 
these two new categories.
 ► Castori et al showed that patients may move from the HSD cate-
gory into hEDS over time: they also emphasised that the approach 
to management and the prognosis in terms of disability are the 
same.45 One may therefore conclude that health needs across these 
groups are similar.
combined diagnosed prevalence of JHS/EDS within a 
population.
Although common features of these conditions are 
arthralgia, soft tissue injury and joint instability,6 over 
the last two decades it has become clear that their clin-
ical features are not limited to musculoskeletal and 
cutaneous involvement, but are multisystemic.7–9 In the 
special edition of the American Journal of Medical Genetics 
dedicated to EDS in March 2017, papers covered links 
to cardiovascular autonomic10 and gastrointestinal 
dysfunction11 as well as psychiatric and neurodevelop-
mental disorders.5 12 Chronic disabling fatigue13 and 
pain syndromes14 were also recognised as common and 
multifactorial issues. Gynaecological15 16 and obstetric17 
issues are also reported in this population. There is also 
an emerging link with the potentially life- threatening 
condition of mast cell activation syndrome.18 19 There is 
some emerging evidence hinting that nutritional defi-
ciencies20 21 may play a key role, both seeming to be more 
prevalent in these patients and possibly implicated in the 
development of some of the complications.
Early diagnosis is found to be crucial to patients22 to 
enable the provision of appropriate treatment, as well as to 
prevent later onset complications.7 Establishing the diag-
nosis of EDS/hypermobility spectrum disorder (HSD) is 
often problematic for patients, which interferes with the 
early detection, treatment and prevention of further esca-
lations of recognised symptoms, disability and more elab-
orate complications. A mean of 14 years elapses between 
the first clinical manifestations and the actual diagnosis.23 
For 25% of patients, this delay lasts over 28 years.23 “A 
misdiagnosis was given to 56% of patients [resulting in] 
inappropriate treatment in 70% of the patients…. For 
86% of the patients, the delay in diagnosis was considered 
responsible for deleterious consequences.” 23(p.137)
It is possible that some of these difficulties arise from 
the widespread belief among clinicians that EDS is rare. 
It is therefore of clinical importance to establish better 
estimates of current prevalence. Conventional studies 
tend to be based in restricted clinical settings, such as 
rheumatology clinics, and are therefore limited by the 
number of recruited patients and biased by severity/type 
of patients referred. It has been shown that using linked 
health data is an economic and effective alternative to 
performing de novo longitudinal studies, including rare 
conditions.24 25 We used routinely held data from primary 
and secondary care sources to examine the epidemiology 
of people with a diagnostic code for EDS/JHS in Wales. 
We then conducted a nested case–control study to study 
the number of diagnoses across all body/disease systems 
and prescription usage to test the widespread belief that 
these conditions are primarily musculoskeletal in nature, 
rather than multisystem disorders.
MEthODS
Study design: nationwide electronic cohort study
Anonymised record linkage and hosting is carried out 
in the Secure Anonymised Information Linkage (SAIL) 
databank26 on routinely collected data held in health and 
social care datasets. All data within the SAIL gateway are 
treated in accordance with the Data Protection Act 2018 
and complies with the EU General Data Protection Regu-
lation (GDPR).
We used data from a variety of datasets between 1 July 
1990 and 30 June 2017 to create the anonymised e- co-
hort and case–control studies. The primary care data 
cover about 80% of all coded information held by general 
practitioners (GPs) in Wales. The Welsh Demographics 
Service (WDS) contains key statistics, such as gender, 
week of birth, date of death and practice migration status 
for everyone in Wales registered with a GP. The Patient 
Episode Database for Wales (PEDW) contains all inpa-
tient hospital admissions to a Welsh hospital. WDS and 
PEDW data are available for the whole of Wales. The SAIL 
databank enables the anonymised matching of individ-
uals across these different datasets using a person level 
anonymised linkage field (ALF).26
Cohort preparation
We identified Welsh residents with a Read Version 227 
diagnostic code of EDS or JHS in primary care data or 
International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10) diag-
nostic codes28 in secondary care data (hospital admis-
sions) between 1 July 1990 (or the start of the dataset 
if later) and 30 June 2017. This date marks the end of 
maximum data coverage across all datasets. The EDS 
subclassification in Read Version 2 contains some, but not 
all, of the subtypes which were in use prior to 1997 and as 
a result, the reliability of any subtype data must be highly 
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Table 1 Clinical coding for EDS and JHS
Read code descriptions 
(based on pre-1997 
nomenclature)
EDS type according to the 
Villefranche criteria
EDS type according to the 
March 2017 criteria
Read code 
version 2 ICD-10 code
Ehlers- Danlos syndrome PGy2. Q79.6
Ehlers- Danlos syndrome type I Classical type Classical EDS PGy20
Ehlers- Danlos syndrome type II PGy21
Ehlers- Danlos syndrome type III Hypermobility type Hypermobile EDS or 
hypermobility spectrum 
disorder
PGy22
Ehlers- Danlos syndrome type IV Vascular type Vascular EDS PGy23
Ehlers- Danlos syndrome type V X- linked type No longer classified as EDS PGy24
Ehlers- Danlos syndrome type VI Kyphoscoliotic type Kyphoscoliotic EDS PGy25
Ehlers- Danlos syndrome type 
VII
Arthrochalasia type
Dermatosparaxis type
Arthrochalasia EDS
Dermatosparaxis EDS
PGy26
Ehlers- Danlos syndrome type 
VIII
Periodontitis type Periodontal EDS PGy27
Hypermobility syndrome
(JHS according to the Brighton 
Criteria)
Hypermobility type Hypermobile EDS or 
hypermobility spectrum 
disorder
N235. 728.5
EDS, Ehlers- Danlos syndrome; ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; JHS, 
joint hypermobility syndrome.
questionable (see table 1). Due to the lack of available 
correct subcodes for EDS subtypes, the fact that the over-
whelming majority of patients simply had the header code 
(86% of those coded as EDS, with a further 12% coded 
as hypermobile EDS (hEDS)), and that other EDS types 
are genuinely rare, all codes for EDS were combined. 
ICD-10 codes do not distinguish between any subtypes of 
EDS (see table 1). Only ALFs with good matching status 
were included in the study, that is, direct match on either 
National Health Service (NHS) number or on surname, 
first name, postcode, date of birth and gender; or fuzzy 
matching with a probability of ≥90%.
We created one dataset for diagnoses in the GP data 
and another for diagnoses in the hospital data. Both data-
sets were linked to the week of birth, gender and date 
of death information in WDS on their ALF and then 
combined to create a cohort of people with EDS/JHS in 
either GP or hospital data, identifying any duplications 
and keeping the earliest diagnosis date for any individual 
appearing in both datasets.
Analysis
Data linkage and data preparation within the SAIL data-
bank were conducted using IBM DB2 10.5 SQL. Data 
were then imported into R (Version 3.4.1),29 which was 
used for all statistical analyses. The mean age at first diag-
nosis between male and female subjects was compared 
and CIs of the difference calculated.
The denominator of the diagnosed prevalence and inci-
dence of EDS and JHS in secondary care was calculated 
based on the total number of individuals with recorded 
gender, registered and living in Wales between 01 July 
1990 and 30 June 2017 for each full year of the study, 
respectively. The prevalence and incidence in primary 
care denominator was further adjusted to include only 
people living in Wales and whose GP practice was contrib-
uting data to SAIL. The prevalence and incidence in 
primary and secondary care was then added together 
to create an overall estimate of the prevalence and inci-
dence in Wales.
Case–control comparison
A nested case–control method was used. Each case was 
matched to four controls with the same gender and 
similar age profiles (within 45 days of the week of birth). 
We implemented strict criteria for selection to the case–
control cohort. Both cases and controls had to (1) have 
uninterrupted GP registrations for 1 year before and 1 year 
after the date of the relevant diagnosis (or died during 
follow- up); (2) be registered with a GP submitting data to 
SAIL either at the matching date or afterwards; (3) have 
been registered with a GP that consistently recorded data 
across their patient profile. The latter avoids diagnoses 
that were retrospectively entered for a time period when 
the GP practice did not fully implement the use of elec-
tronic records (less than 10% of the data they recorded 
during 2009). Although this reduced the number of cases 
and controls we were able to analyse, it avoids data quality 
bias, especially during the early years of this study, when 
GPs were converting to the use of computer systems and 
databases. Controls with any type of diagnosed heredi-
tary connective tissue disorder were excluded. Prelim-
inary analysis of the combined cohort indicated that 
adjustment for deprivation was not necessary (ie, equal 
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Figure 1 Flow diagram of EDS/JHS cohort and case–control cohort creation. EDS, Ehlers- Danlos syndrome; GP, general 
practitioner; ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; JHS, joint 
hypermobility syndrome; SAIL, Secure Anonymised Information Linkage
distribution of people across deprivation quintiles). We 
then calculated ORs between cases and controls using 
Read chapters (excluding the Read codes for EDS and 
JHS). This method counts the number of people with 
a code in each category; multiple codes for the same 
person in the same category are therefore not included. 
All results that affected at least 5 cases or 20 controls were 
visualised using forest plots.
Ethical approval
The study design uses anonymised data and therefore 
the need for ethical approval and participant consent was 
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Figure 3 Prevalence of coded diagnosis of JHS/EDS in 
primary care, hospital inpatient and combined over time. 
EDS, Ehlers- Danlos syndrome; GP, general practitioner; JHS, 
joint hypermobility syndrome.
Figure 2 Age at first coded diagnosis of EDS/JHS by age 
group and gender. EDS, Ehlers- Danlos syndrome; JHS, joint 
hypermobility syndrome.
waived by the approving Institutional Review Board, the 
UK National Health Service Research Ethics Committee. 
The SAIL independent Information Governance Review 
Panel approved the study.
Patient and public involvement
Two of the authors of this paper have been diagnosed with 
symptomatic joint hypermobility disorders. This study 
used routinely collected data, and we were not able to 
involve members of the public but will be disseminating 
our findings widely, including directly to patients via social 
media and through our links with patient organisations.
rESultS
EDS/JhS in primary care data
5355 individuals with a diagnosis of either EDS or JHS 
with valid birth and gender information were identified. 
Of these, 4654 (87%) had a diagnosis of JHS and 701 
(13%) of EDS. The Read code for the EDS subtype was 
only used for 136 (19%) individuals with 114 (16%) iden-
tified as EDS- hypermobility type and 22 (3%) as other 
EDS subtypes. 3759 (70%) of those diagnosed with EDS/
JHS were women (see figure 1).
EDS/JhS in hospital data
A total of 1298 individuals were found in the hospital data 
of whom 970 (75%) were women: 745 (57%) had a diag-
nosis of JHS and 553 (43%) EDS (see figure 1).
Demographics of combined EDS/JhS cohort
5355 (89%) of the cases could be found in the primary 
care data with the remainder in the hospital cohort. 
Combining the results from primary and secondary care 
led to a cohort of 6021 distinct individuals. 5064 (84%) 
were coded with JHS and 957 (16%) with EDS. 4244 
(70%) of patients were women. The age at first diagnosis 
peaked in the age group 5–9 years for men and 15–19 years 
for women (see figure 2). There was a significant differ-
ence of 8.5 years in the mean age of diagnosis between 
men and women (95% CI: 7.70 to 9.22): 9.6 years in EDS 
(95% CI: 6.85 to 12.31) and 8.3 years in JHS (95% CI: 7.58 
to 9.11). 72% of men were diagnosed during childhood 
(age <18 years) in contrast to only 41% of women.
2016/2017 is the latest year for which we have complete 
data and could therefore derive prevalence. During this 
year, 2 668 902 people were registered with a GP in Wales 
submitting data to SAIL, of whom 4598 had a diagnostic 
code of EDS/JHS which first appeared in the primary 
care data (172 in 100 000). A further 711 people out of 
the 3 239 153 registered with any GP in Wales during 
2016/2017 had an EDS/JHS diagnosis which first 
appears in secondary care data (22 in 100 000). There 
is an increasing rate of coded diagnoses throughout the 
period. Assuming that the GP data are representative of 
the whole of Wales this leads to a combined point prev-
alence of 194 in 100 000 at the end of the study period. 
This corresponds to about 10 cases in a practice of 5000 
patients (see figure 3). The incidence of EDS/JHS over 
this time period is shown in online supplementary figure 
1.
Factors associated with JhS/EDS
2597 cases had good GP data coverage at the age of 
diagnosis and could be matched by age and gender with 
controls (see figure 1). 1340 cases (men: 561; women: 
779) were first diagnosed before the age of 18 years and 
1254 cases (men: 229; women: 1025) above this age. The 
people in the nested case–control cohort were slightly 
older than the overall cohort (data not shown here).
Looking at the time frame of 1 year on either side of the 
first coded diagnosis of EDS/JHS among young people 
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Figure 4 ORs of Read chapter diagnoses for (A) young people (<18 years of age) and (B) adults (≥18 years of age) within 
12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (perinatal 
conditions, Chapter Q, are not shown as neither young people nor adults had the required minimum number of cases/controls). 
EDS, Ehlers- Danlos syndrome; JHS, joint hypermobility syndrome.
(age <18 years), there were significantly more additional 
diagnoses in 16 out of 20 Read code disease categories 
compared with their controls (see figure 4A). The top 
three Read diagnosis chapters with increased odds for 
the EDS/JHS cohort were for musculoskeletal conditions 
(OR 9.36, 95% CI: 7.98 to 11.00), congenital anomalies 
(OR 5.89; 95% CI: 3.98 to 8.80) and mental disorders 
(OR 4.16; 95% CI: 3.29 to 5.27).
People who were diagnosed as adults (age ≥18 years) 
had also significantly more diagnoses in 16 out of 20 Read 
code categories than their controls (see figure 4B). The 
top three Read diagnosis chapters for adults with higher 
odds in the EDS/JHS cohort were musculoskeletal disor-
ders (OR 7.95; 95% CI: 6.95 to 9.12), congenital anoma-
lies (OR 5.18; 95% CI: 2.78 to 9.78) and symptoms, signs 
and ill- defined conditions (OR 2.9; 95% CI: 2.5 to 3.37). 
Circulatory system disease (OR 2.29; 95% CI: 1.83 to 2.86) 
and mental disorders remained significant (OR 1.87; 
95% CI: 1.57 to 2.22), but not to the same extend as they 
were for young people.
Young people showed significantly higher odds for 
prescriptions in 14 out of 17 Read code categories then 
their controls (see figure 5A). The top three prescrip-
tions of Read chapters with increased odds for the EDS/
JHS cohort were for (1) musculoskeletal drugs (OR 3.65; 
95% CI: 3.18 to 4.18), (2) gastrointestinal drugs (OR 3.02; 
95% CI: 2.54 to 3.58) and (3) haematology/dietetic drugs 
(OR 2.54; 95% CI: 2.06 to 3.11).
Adults had significantly higher odds of prescriptions 
for 15 out of 17 Read code categories (see figure 5B). 
The top three prescriptions with higher odds for EDS/
JHS people were for (1) musculoskeletal drugs (OR 5.17; 
95% CI: 4.53 to 5.9), (2) central nervous system drugs 
(OR 3.9; 95% CI: 3.41 to 4.46) and (3) chemotherapy/
immunosuppressant drugs (OR 3.03; 95% CI: 1.89 to 
4.8). Gastrointestinal drugs (OR 2.85; 95% CI: 2.5 to 3.24) 
and haematology/dietetic drugs (OR 2.21; 95% CI: 1.9 to 
2.57) remain significant, but at slightly lower levels than 
in the young EDS/JHS population.
DISCuSSIOn
This work examined the epidemiology of EDS and JHS 
and found a combined diagnosed prevalence of 194.2 per 
100 000 (0.19%) or 1 in 500 people in Wales; hEDS or 
HSD within the 2017 classification. We found a steadily 
increasing rate of diagnosis over the past 27 years (see 
online supplementary figure 1), as well as higher rates of 
copyright.
 o
n
 N
ovem
ber 21, 2019 at Swansea University. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031365 on 4 November 2019. Downloaded from 
7Demmler JC, et al. BMJ Open 2019;9:e031365. doi:10.1136/bmjopen-2019-031365
Open access
Figure 5 ORs of Read chapter prescriptions for young people (<18 years of age) and adults (≥18 years of age) within 12 months 
before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma 
appliances, Chapters Q and S, are not shown as neither young people nor adults had the required minimum number of cases/
results). EDS, Ehlers- Danlos syndrome; JHS, joint hypermobility syndrome.
diagnoses for other conditions and prescriptions within 
12 months (before and after) of the recorded first diag-
nosis in most categories. This suggests that hEDS/HSD, 
when considered together, do not meet the definition 
of rare conditions23 and have widespread effects across 
multiple body systems.
It is well- known that EDS is poorly recognised in chil-
dren30 31 and initial symptoms and EDS- associated diag-
noses can appear to be simply a ‘normal’ pattern of 
childhood illness when taken as an isolated event. Further-
more, children with hEDS often present with symptoms 
that can lead to a misdiagnosis of mental illness or consid-
eration of child abuse.12 32 Suspicion of abuse has been 
shown to be extremely damaging to the mental health of 
the parent(s) and can lead to an avoidance of accessing 
healthcare or other public services, such as schools.33 The 
prolonged and sometimes traumatic diagnosis and/or 
misdiagnosis process in EDS can lead to further disen-
gagement with services.34 The lack of a timely diagnosis 
has great implications for disease management and 
progression and impedes the appropriate consideration 
of surgical interventions7 35–38 as well as pregnancy and 
birth planning.17 It is perhaps only in stepping back to 
look at the pattern of effects across multiple body systems 
that practitioners might begin to consider a connective 
tissue disorder.
Strengths and limitations
The strength of this study is that we were able to combine 
diagnostic codes from several primary and secondary 
healthcare providers to create a large cohort of individ-
uals with EDS/JHS. We have 27 years of data with at least 
11 years of very good data coverage in the key datasets, 
which further improves with each data update of the SAIL 
databank; however, data coverage for the first couple of 
years is less comprehensive.
The majority of subjects were identified via their 
primary care data, which is a strength and a weakness. As 
89% of cases were identified through primary care, data 
studies not using primary care data may underestimate 
the prevalence of hEDS/HSD. We are unable to quantify 
how many people are suffering from hEDS or HSD but 
remain undiagnosed. However, we cannot comment on 
the reliability of the diagnoses in the primary care dataset. 
It is also likely that the majority of cases were not actually 
diagnosed in primary care, but their entries were created 
through secondary care contacts, such as outpatient 
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appointments or musculoskeletal assessment clinics, but 
coded data are lacking from these sources.
Although a snapshot of Read chapters codes that are 
more prevalent in our JHS/EDS cohort does not allow 
us to look at specific diagnoses and prescriptions, they 
can all be matched to conditions associated with EDS/
JHS in the literature, for instance pain, fatigue, cardio-
vascular, gastrointestinal and gynaecological disorders, 
dysautonomia, mast cell activation as well as urinary 
tract infections.7 It needs to be stressed that these results 
exclude codes for EDS/JHS and that these are not part 
of the results for congenital anomalies or musculoskel-
etal conditions. We hope in future work to examine in 
greater detail these findings of significant differences 
between people with hEDS/HSD and others in order that 
we can better understand the nature of this condition, 
as well as potentially improving diagnostic recognition. 
For instance, immunosuppressant drugs are in the same 
Read chapter as chemotherapy drugs. Higher use of these 
prescriptions in the hEDS/HSD cohort could plausibly 
be linked to the known increased comorbid existence 
of disorders such as inflammatory bowel disease, inflam-
matory arthropathies, systemic lupus erythematosus and 
other autoimmune conditions,39 and is less likely to be 
due to a higher rate of use of chemotherapeutic agents.
We conclude that EDS/HSD are not rare conditions 
and are associated with significantly increased odds of 
additional diagnoses and use of medications across many 
body systems. There is a large gender difference in the 
age of diagnosis, with many women not diagnosed until 
adulthood. Early diagnosis, however, is crucial to patients, 
the administration of preventive therapies, the investiga-
tion of comorbid conditions and the overall management 
process. Further research is needed to understand patient 
pathways, comorbidities and progression of associated 
symptoms and diseases. Health services should be aware 
of these findings for the provision of training, diagnostic 
and treatment services for the many tens of thousands 
of patients living with these life- changing conditions 
throughout the UK and beyond.
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